Debiopharm further describes AbYlink as a one-step method that results in stable conjugation at defined and invariable sites on the Fc domain of an antibody, with no impact on antigen-binding regions, ...

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 ...

Many patent applicants currently face difficulty in obtaining antibody claims because of written description and enablement ...

Debiopharm Research & Manufacturing S.A. (Debiopharm, a Swiss-based global biopharmaceutical company aiming to cure cancer and ...

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 150+ ...

In 2021, research led by Ryan Flynn, MD, PhD, and his mentor, Nobel laureate Carolyn Bertozzi, PhD, opened a new chapter in biology, characterizing a new kind of player on the cell surface: glycoRNAs.

Researchers show that glycoRNAs, uncovered by the lab of Nobel Laureate, Carolyn Bertozzi, can be used to fight cancer.

The US Food and Drug Administration (FDA) has approved an investigational new drug (IND) application from Aclaris ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Antibodies are best known for their ability to latch onto and neutralize bacteria, viruses and other pathogens. But these ...

Additionally, in the framework of a licensing agreement and a collaborative endeavor to support innovative research, Debiopharm and Oncodesign Services will present promising new data illustrating how ...

Antibody Solutions, a leading provider of fit-for-purpose antibody discovery services, announced today that for the first ...